Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Mechinaud

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Pediatrics|July 1, 1997
Cutaneous involvement in children with acute lymphoblastic leukemia or lymphoblastic lymphoma. The Children's Leukemia Cooperative Group of the European Organization of Research and Treatment of Cancer (EORTC)F Millot, A Robert, Y Bertrand, et al.
Leukemia & Lymphoma|March 14, 1998
In vivo infusion of anti-LFA-1 and anti-CD2 antibodies prevents graft failure after HLA partially incompatible bone marrow transplantation in children with high risk acute lymphoblastic leukaemiaM Cavazzana-Calvo, N Jabado, P Bordigoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 1997
NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric OncologyC Coze, O Hartmann, J Michon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de MoelleG Michel, G Socié, F Gebhard, et al.
Journal of Medical Genetics|June 15, 2010
Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemiaB Pérez, F Mechinaud, C Galambrun, et al.
Bone Marrow Transplantation|June 12, 2002
Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapyS Vigouroux, N Milpied, J M Andrieu, et al.
British Journal of Cancer|September 20, 2000
Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncologyV Minard, O Hartmann, M C Peyroulet, et al.
Thrombosis Research|April 29, 2019
Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemiaM K Mateos, T N Trahair, C Mayoh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative GroupA Thyss, S Suciu, Y Bertrand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trialF Millot, S Suciu, N Philippe, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Pediatrics|July 1, 1997
Cutaneous involvement in children with acute lymphoblastic leukemia or lymphoblastic lymphoma. The Children's Leukemia Cooperative Group of the European Organization of Research and Treatment of Cancer (EORTC)F Millot, A Robert, Y Bertrand, et al.
Leukemia & Lymphoma|March 14, 1998
In vivo infusion of anti-LFA-1 and anti-CD2 antibodies prevents graft failure after HLA partially incompatible bone marrow transplantation in children with high risk acute lymphoblastic leukaemiaM Cavazzana-Calvo, N Jabado, P Bordigoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 1997
NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric OncologyC Coze, O Hartmann, J Michon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de MoelleG Michel, G Socié, F Gebhard, et al.
Journal of Medical Genetics|June 15, 2010
Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemiaB Pérez, F Mechinaud, C Galambrun, et al.
Bone Marrow Transplantation|June 12, 2002
Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapyS Vigouroux, N Milpied, J M Andrieu, et al.
British Journal of Cancer|September 20, 2000
Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncologyV Minard, O Hartmann, M C Peyroulet, et al.
Thrombosis Research|April 29, 2019
Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemiaM K Mateos, T N Trahair, C Mayoh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative GroupA Thyss, S Suciu, Y Bertrand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trialF Millot, S Suciu, N Philippe, et al.
Pageof 6